(Q38769271)

6 September 2017

title

Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors (English)

1 reference

6 September 2017

1 reference

Bing-Lan Zhang

1

1 reference

6 September 2017

Di-Yuan Qin

2

1 reference

6 September 2017

Ze-Ming Mo

3

1 reference

6 September 2017

Yi Li

4

1 reference

6 September 2017

Wei Wei

5

1 reference

6 September 2017

Yong-Sheng Wang

6

1 reference

6 September 2017

Wei Wang

7

1 reference

6 September 2017

Yu-Quan Wei

8

1 reference

6 September 2017

publication date

11 March 2016

1 reference

Science in China. Series C: Life Sciences

6 September 2017

published in

1 reference

6 September 2017

volume

59

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

340-348

1 reference

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Stromal fibroblasts in cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Monoclonal antibody-induced cytokine-release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

TRUCKs: the fourth generation of CARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

21 January 2018

The tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Endothelin B receptor, a new target in cancer immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

NK cell-based cancer immunotherapy: from basic biology to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

CAR mechanics: driving T cells into the MUC of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

The integration of T cell migration, differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

The role of heparan sulphate in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Roadblocks to success for RNA CARs in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Trafficking of T cells into tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5027-4

10.1007/S11427-016-5027-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1011504316

0 references

1 reference